ArticleEnvironment international2021
Per- and polyfluoroalkyl substances and calcifications of the coronary and aortic arteries in adults with prediabetes: Results from the diabetes prevention program outcomes study.
Article in Environment international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Exposure to Endocrine-Disrupting Chemicals and Congenital Heart Diseases: The Pooled Results Based on the Current Evidence.Pediatric cardiology · 2025Pooled it
- Understanding the Impact of Perfluorinated Compounds on Cardiovascular Diseases and Their Risk Factors: A Meta-Analysis Study.International journal of environmental research and public health · 2021Pooled it
- Imaging and Molecular Biomarkers of PFAS-Related Vascular Aging: A Narrative Review.International journal of molecular sciences · 2026Review
- Per- and Polyfluoroalkyl Substances Exposure and Ischemic Heart Disease: Emerging Evidence from the Literature.Antioxidants (Basel, Switzerland) · 2026Review
- PFAS and cardiovascular risk : The effects of exposure to perfluoroalkyl and polyfluoroalkyl substances on cardiovascular health.Wiener klinische Wochenschrift · 2026Review
- Effect of Perfluorooctanesulfonic Acid on Fibrin Clot Properties and Thrombin Generation: Linking Environmental Pollution with Cardiovascular Diseases.Journal of cardiovascular development and disease · 2026Article
- Per- and polyfluoroalkyl substances: A novel risk factor for cardiovascular disease.Ecotoxicology and environmental safety · 2026Review
- Associations of Perfluoroalkyl and Polyfluoroalkyl Substances With Cardiovascular Disease Incidence in Adults With Prediabetes: Findings From the Diabetes Prevention Program.Journal of the American Heart Association · 2026Article
- Exploring the Association Between Per- and Polyfluoroalkyl Substances Exposure and the Risk of Stroke: A Systematic Investigation Using NHANES Data Analysis, Network Toxicology and Molecular Docking Approaches.Brain and behavior · 2025Article
- Endocrine-disrupting chemicals exposure: cardiometabolic health risk in humans.Cardiovascular diabetology · 2025Review
- Evaluating the Vascular Risk of PFCs: An Integrated XGBoost-Driven Structure-Activity Prediction and Experimental Validation Study.Environment & health (Washington, D.C.) · 2025Article
- Associations between per- and polyfluoroalkyl chemicals and abdominal aortic calcification in middle-aged and older adults.Journal of advanced research · 2025Article
- Association of Per- and Polyfluoroalkyl Substance Exposure with Coronary Stenosis and Prognosis in Acute Coronary Syndrome.Environment & health (Washington, D.C.) · 2025Article
- Per- and polyfluoroalkyl substances, apolipoproteins and the risk of coronary heart disease in US men and women.Environmental health : a global access science source · 2024Article
- The efficacy of wastewater treatment plant on removal of perfluoroalkyl substances and their impacts on the coastal environment of False Bay, South Africa.Environmental science and pollution research international · 2024Article
- Perfluoroalkyl/Polyfluoroalkyl Substances: Links to Cardiovascular Disease Risk.Circulation research · 2024Review
- Exposure to specific polyfluoroalkyl chemicals is associated with cardiovascular disease in US adults: a population-based study.Frontiers in cardiovascular medicine · 2024Article
- Exposure to per- and polyfluoroalkyl substances is associated with impaired cardiovascular health: a cross-sectional study.Frontiers in public health · 2024Article
- Association of per- and polyfluoroalkyl substances with constipation: The National Health and Nutrition Examination Survey (2005-2010).PloS one · 2024Article
- Associations of perfluoroalkyl substances (PFAS) with lipid and lipoprotein profiles.Journal of exposure science & environmental epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 2 countries.
Funding
Abstract
backgroundPer- and polyfluoroalkyl substances (PFAS) are endocrine disrupting chemicals that have been associated with cardiovascular risk factors including elevated body weight and hypercholesterolemia. Therefore, PFAS may contribute to the development of atherosclerosis and cardiovascular disease (CVD). However, no previous study has evaluated associations between PFAS exposure and arterial calcification. METHODS AND
resultsThis study used data from 666 prediabetic adults enrolled in the Diabetes Prevention Program trial who had six PFAS quantified in plasma at baseline and two years after randomization, as well as measurements of coronary artery calcium (CAC) and ascending (AsAC) and descending (DAC) thoracic aortic calcification 13-14 years after baseline. We performed multinomial regression to test associations between PFAS and CAC categorized according to Agatston score [low (<10), moderate (11-400) and severe (>400)]. We used logistic regression to assess associations between PFAS and presence of AsAC and DAC. We adjusted models for baseline sex, age, BMI, race/ethnicity, cigarette smoking, education, treatment assignment (placebo or lifestyle intervention), and statin use. PFAS concentrations were similar to national means; 53.9% of participants had CAC > 11, 7.7% had AsAC, and 42.6% had DAC. Each doubling of the mean sum of plasma concentrations of linear and branched isomers of perfluorooctane sulfonic acid (PFOS) was associated with 1.49-fold greater odds (95% CI: 1.01, 2.21) of severe versus low CAC. This association was driven mainly by the linear (n-PFOS) isomer [1.54 (95% CI: 1.05, 2.25) greater odds of severe versus low CAC]. Each doubling of mean plasma N-ethyl-perfluorooctane sulfonamido acetic acid concentration was associated with greater odds of CAC in a dose-dependent manner [OR = 1.26 (95% CI:1.08, 1.47) for moderate CAC and OR = 1.37 (95% CI:1.07, 1.74) for severe CAC, compared to low CAC)]. Mean plasma PFOS and n-PFOS were also associated with greater odds of AsAC [OR = 1.67 (95% CI:1.10, 2.54) and OR = 1.70 (95% CI:1.13, 2.56), respectively], but not DAC. Other PFAS were not associated with outcomes.
conclusionsPrediabetic adults with higher plasma concentrations of select PFAS had higher risk of coronary and thoracic aorta calcification. PFAS exposure may be a risk factor for adverse cardiovascular health among high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.